DBV Technologies Shares Jumps As FDA Lifts Partial Hold On Pivotal Trial For Peanut Allergy Patch
The FDA has lifted the partial clinical hold on DBV Technologies (NASDAQ:DBVT) VITESSE Phase 3 clinical trial that will evaluate the modified…
US Stocks Look To Close Volatile Week On A High — Fed’s Preferred Inflation Gauge, New Home Sales Data, Tesla, AMC In Spotlight
Stocks could be in for a higher opening on Friday, as indicated by the trading in the index futures. Key economic data will have a bearing on the day’s market direction, although conviction in the potential move could be less due to the thin trading volume that is characteristic of pre-holiday trade.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million.
Algoma Steel Group, Sandstorm Gold And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.
11 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers
Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial, FDA Places Partial Clinical Hold On Co.’s VITESSE Phase 3 Clinical Study
DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE